1. Investigation launched into proposed sale of Avadel Pharmaceuticals to Alkermes. 2. Avadel shareholders to receive $18.50 per share, plus contingency of $1.50. 3. Transaction's adequacy and valuation are being scrutinized by a law firm.
FAQ
Why Bullish?
The proposed acquisition of Avadel could enhance Alkermes' portfolio, similar to past acquisitions that boosted market confidence, such as Allergan's purchase of Kythera. Additionally, the contingent payment tied to FDA approval indicates potential for future earnings growth.
How important is it?
The article focuses on a significant merger that could transform Alkermes' drug pipeline and market position, warranting attention from investors.
Why Long Term?
The deal could positively impact Alkermes' revenue in the long term, especially if LUMRYZ™ receives FDA approval. Historical cases, such as Acadia Pharmaceuticals' acquisition strategy, show sustained market performance following successful integrations.
Investigation into Avadel Pharmaceuticals Sale to Alkermes by Kahn Swick & Foti
Former Louisiana Attorney General Charles C. Foti, Jr., Esq. and the law firm Kahn Swick & Foti, LLC ("KSF") are actively investigating the proposed acquisition of Avadel Pharmaceuticals plc (NasdaqGM: AVDL) by Alkermes plc (NasdaqGS: ALKS). The proposed transaction raises questions regarding the adequacy of its terms for Avadel's shareholders.
Details of the Proposed Transaction
Under the terms of the sale, shareholders of Avadel will receive $18.50 per share. Additionally, they will be granted a non-transferable contingent value right, which may provide an extra $1.50 per share, contingent upon the final FDA approval of LUMRYZ™ for the treatment of idiopathic hypersomnia in adults by the end of 2028.
Purpose of the Investigation
KSF aims to determine whether the proposed financial consideration adequately reflects the value of Avadel Pharmaceuticals. They are particularly interested in the circumstances that led to this valuation to assess if shareholders are receiving a fair deal.
Call to Action for Shareholders
If you believe that the proposed sale undervalues Avadel Pharmaceuticals and wish to discuss your legal rights regarding the transaction, KSF invites you to reach out. You can contact KSF Managing Partner Lewis S. Kahn via email at lewis.kahn@ksfcounsel.com or call toll-free at 855-768-1857. Further details can also be found on their website at KSF Counsel.
About Kahn Swick & Foti
Kahn Swick & Foti, LLC is a recognized law firm with significant experience in shareholder advocacy. The firm, which includes former Louisiana Attorney General Charles C. Foti, Jr., is dedicated to ensuring the rights of shareholders are protected during significant corporate transactions.
Contact Information
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
Connect with KSF
Stay updated by following KSF on social media platforms: Facebook, Instagram, YouTube, TikTok, and LinkedIn.